Study guide

5.1 Estimands and Intercurrent Events

ACRP CCRA Certified Clinical Research Associate Study Guide 2026 Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Format, Eligibility and Registration

1.1 Exam Format, Eligibility and Current References 1.2 Registration, Fees and Candidate Decisions

2 Chapter 2: CRA Responsibilities and Study Planning

2.1 The CRA Role, Data Integrity and Product Oversight 2.2 Official Blueprint and Study Strategy

3 Chapter 3: Protocols, Endpoints and Trial Design

3.1 Protocol Elements and Endpoint Hierarchy 3.2 Endpoint Interpretation and Eligibility Rationale 3.3 Eligibility Verification and Trial Designs

4 Chapter 4: Bias Control, Blinding and Product Information

4.1 Bias, Randomisation and Comparator Controls 4.2 Unblinding and Investigator Brochure Content 4.3 Reference Safety Information and IB Updates

5 Chapter 5: Estimands and Device Instructions

5.1 Estimands and Intercurrent Events 5.2 Device Instructions, Configuration and Training

6 Chapter 6: Ethical Foundations and Independent Oversight

6.1 Ethical Foundations and the 2024 Declaration of Helsinki 6.2 Vulnerability, Voluntariness and Compensation 6.3 IRB/IEC Composition and Independent Review

7 Chapter 7: Ethics Communication and Informed Consent

7.1 Ethics Reporting, Approval Status and Version Control 7.2 Informed Consent Information and Meaningful Choice 7.3 Consent Documentation, Special Circumstances and Updates

8 Chapter 8: Recruitment, Retention and Confidentiality

8.1 Ethical Eligibility, Recruitment and Retention 8.2 Privacy, Confidentiality and Appropriate Access

9 Chapter 9: Safety Definitions and Classification

9.1 Adverse Event Definitions and Actual Life-Threatening Risk 9.2 Seriousness, Severity and Medical Importance 9.3 Causality, Expectedness and Reference Safety Information

10 Chapter 10: Safety Detection, Reporting and Oversight

10.1 Detecting Events, AESIs and Collection Windows 10.2 Expedited Reporting and the Sponsor Awareness Clock 10.3 Immediate Site Reporting and Independent Safety Oversight

11 Chapter 11: Follow-Up, Adherence and Conflicts

11.1 Safety Communications, Reconciliation and Follow-Up 11.2 Adherence, Discontinuation and Participant Choice 11.3 Conflicts of Interest and Prorated Payments

12 Chapter 12: Development Stages and Product Management

12.1 Nonclinical Background and Human Pharmacology 12.2 Exploratory, Confirmatory and Therapeutic-Use Studies 12.3 Product Storage, Labelling and Excursion Response

13 Chapter 13: Accountability, Integrity and Regulatory Status

13.1 Product Accountability and Adherence Calculations 13.2 Potential Fraud, Misconduct and Evidence Preservation 13.3 Submissions, Authorisation Status and Trial Reporting

14 Chapter 14: Current GCP Principles and Delegation

14.1 The Eleven Current GCP Principles 14.2 Proportionality and Investigator Oversight 14.3 Delegation, Qualifications and Task Authority

15 Chapter 15: Oversight, Protocol Control and Amendments

15.1 Clinical Oversight and Immediate-Hazard Changes 15.2 Deviation Classification and Resolution

16 Chapter 16: Implementation and Trial Responsibilities

16.1 Amendment Implementation and Communication 16.2 Sponsor, Investigator and Service-Provider Roles

17 Chapter 17: Quality Planning, Root Causes and CAPA

17.1 Quality Planning and Risk Management 17.2 Root Cause Analysis and CAPA Design 17.3 CAPA Implementation and Effectiveness Verification

18 Chapter 18: Risk Assessment and Monitoring Methods

18.1 Risk Assessment and Centralised Surveillance 18.2 Monitoring Methods and Source Review

19 Chapter 19: Quality Metrics, Plans and Communication

19.1 KRIs, Acceptable Ranges and Trial-Level Quality 19.2 Monitoring Plans, Co-Monitoring and Communication

20 Chapter 20: Site Qualification and Readiness

20.1 Site Qualification and Investigator Capacity 20.2 Recruitment Feasibility and Evidence-Based Site Selection 20.3 Site Readiness and Activity-Specific Release

21 Chapter 21: Initiation, Equipment and Supplies

21.1 Initiation Training and Readiness Walkthroughs 21.2 Equipment, Maintenance and Study Supplies

22 Chapter 22: Samples, Diagnostics and Financial Feasibility

22.1 Specimens, Diagnostic Results and Rater Quality 22.2 Contracts, Budgets and Operational Feasibility

23 Chapter 23: Interim Monitoring and Reporting

23.1 Interim Visit Preparation and Consent Review 23.2 Monitoring Eligibility, Safety and Products 23.3 Investigator Debrief and Monitoring Reports

24 Chapter 24: Essential Records, Audits and Findings

24.1 Essential Records and Site/Sponsor Reconciliation 24.2 Version History, Resolution Evidence and Noncompliance 24.3 Audits, Inspections and Closure Planning

25 Chapter 25: Close-Out, Retention and Destruction

25.1 Close-Out, Archiving and Continuing Obligations 25.2 Retention, Destruction and Long-Term Access

26 Chapter 26: Source Records and Good Documentation

26.1 Source Records and Foundational ALCOA Principles 26.2 Good Documentation, Completeness and Corrections 26.3 Source Access, Certified Copies and Context

27 Chapter 27: Electronic Systems, Metadata and Queries

27.1 EDC Design and Fit-for-Purpose Systems 27.2 Audit Trails, Electronic Outcomes and Device Choice 27.3 Queries, Coding and Supported Clinical Meaning

28 Chapter 28: Dataset Finalisation and Critical Data

28.1 Safety Reconciliation and Dataset Finalisation 28.2 Critical Data, Acquisition Tools and Interim Findings

5.1 Estimands and Intercurrent Events

Key Takeaways Explain This Topic AI

An estimand specifies treatment, population, variable, intercurrent-event handling and the population summary.

Stopping treatment is not necessarily withdrawal from outcome follow-up.

An intercurrent event and a missing measurement are different concepts.

Last updated: October 2026

Estimands and Intercurrent Events

A CRA needs enough scientific understanding to recognise when site conduct no longer answers the question the protocol intended. An objective states what the study seeks to learn. An endpoint is a measured outcome used to assess that objective. An estimand , described in ICH E9(R1), expresses the treatment effect of interest precisely enough to guide design, collection and analysis. It is more than the name of an outcome variable.

Five attributes help define an estimand: the treatments being compared, the population, the variable or endpoint, how relevant intercurrent events are handled, and the population-level summary. Together they distinguish questions that can sound similar in ordinary language. For example, the average symptom difference after assignment regardless of subsequent rescue medication differs from the effect under a hypothetical situation in which rescue medication was unavailable. The endpoint name may be identical while the scientific question differs.

An intercurrent event happens after treatment initiation and affects interpretation or existence of a measurement associated with the question of interest. Examples include stopping assigned treatment, beginning rescue therapy or dying before an assessment. Missing data means a value needed for the specified analysis was not collected or is unavailable. The concepts are not interchangeable. A person can stop treatment and still provide the planned endpoint; a person can continue treatment but miss a visit.

What different strategies imply for conduct

Approach to an intercurrent event Scientific interpretation Site implication

Treatment policy Assess the outcome despite the event Continue appropriate planned follow-up if the participant agrees

Hypothetical Ask about an outcome under a defined situation without the event Collect the information needed by the prespecified methods; do not invent the hypothetical outcome

Composite variable Incorporate the event into the outcome itself Record the event and its timing accurately

While on treatment Focus on response before the event Accurate treatment and assessment timing is particularly important

Principal stratum Focus on a population defined by potential event behaviour The analysis requires assumptions; the site cannot assign membership by intuition

These descriptions are study concepts, not permission for the CRA to choose an analysis strategy. The sponsor's protocol and statistical plan establish the question and methods. When the operational instructions appear inconsistent, escalate for clarification before the inconsistency becomes widespread. A monitor should not tell one site to stop collecting follow-up because that seems easier to analyse.

A practical follow-up example

A participant stops study medication at week 4 because of nausea. The primary symptom assessment is at week 12, and the protocol seeks the effect of treatment assignment regardless of later medication changes. The participant agrees to remain in outcome follow-up. The site should document the medication stop, the reason, relevant safety information, any rescue treatment and the planned week-12 measurement.

Marking every subsequent visit not applicable merely because dosing stopped would discard information relevant to the question.

Now suppose the participant declines further contact. Their choice controls. Explain available follow-up options without pressure, document the scope of the decision and follow the protocol and applicable rules for already collected data. The importance of a complete endpoint does not authorise unauthorised contact, fabricated scores or a demand for a withdrawal reason. Reliable research includes honestly recorded missing information and its context.

Measurement consistency and meaningful effects

An endpoint definition needs an assessment method, schedule, allowable window, units and handling of important events. A pain instrument completed after a procedure may measure something different from the same instrument completed beforehand. A centrally read image and an informal investigator impression are not automatically interchangeable. Verify the version, training and workflow specified by the study.

Distinguish statistical significance from clinical relevance. A small difference can be statistically persuasive in a large study without being important to participants. A clinically promising difference can remain uncertain when the evidence is imprecise. The monitor does not decide a marketing claim; they help preserve a trustworthy measurement process so the analysis can address the intended question.

Analysis populations and monitoring boundaries

The intention-to-treat principle aims to preserve the comparison created by randomisation. The full analysis set seeks to approximate that ideal, with exclusions justified under the plan. A per-protocol set applies prespecified adherence/deviation criteria and can introduce selection bias. Neither permits a site to delete unfavourable observations. Safety sets may use exposure-based definitions and therefore need not equal an efficacy set.

Before a planned analysis, check that dosing dates, intercurrent events, endpoint records, discontinuation reasons and relevant queries are traceable. Document uncertainty rather than resolving it through a convenient assumption. Ask whether an apparent missing value is truly unavailable, collected elsewhere, not expected under the protocol, or incorrectly classified after stopping treatment. This distinction is a central contribution of monitoring to scientific reliability.

Official sources

Checked October 18, 2026: ICH E6(R3), Principles and Annex 1 , ICH E9 , ICH E9(R1) , ICH E8(R1) .